Frank E. Stockdale

Clinical Focus

• Cancer > Breast Cancer
• Breast Cancer - Medical Oncology
• Oncology
• Newly Diagnosed Breast Cancer
• Metastatic Breast Cancer

Honors and Awards

• Fellow, Guggenheim Foundation (1983)
• AAP, American Association of Physicians (1976)
• ASCI, American Society for Clinic Investigation (1974)
• Elected, Best Doctors in America (2006-2010)

Professional Education

Web Site Links

• http://med.stanford.edu/labs/frank_stockdale/

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information

Research Interests

The focus of the research program are clinical trials in breast cancer. Clinical trials aim to investigate treatments for women with breast cancer who are newly diagnosed or have had a recurrence of breast cancer. Trials include participation in the national breast cancer study groups, ECOG and NSABP, as well as the development of new chemotherapy programs. Of particular interest are adjuvant therapy, treatment of metastatic disease, methods for treatment of locally advanced breast cancer and inflammatory breast cancer. Laboratory work has centered on the mechanisms of how cells acquire specific fates during growth and development , providing insights into normal and abnormal mechanisms of growth control.

Clinical Trials

• Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer Recruiting
• Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer Recruiting
• Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer Recruiting
• Anastrozole and Gefitinib Compared With Fulvestrant and Gefitinib in Treating Postmenopausal Women With Recurrent or Metastatic Breast Cancer No longer recruiting
• Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer No longer recruiting

Publications

• New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. Kohrt HE, Olshen RA, Bermas HR, Goodson WH, Wood DJ, Henry S, Rouse RV, Bailey L, Philben VJ, Dirbas FM, Dunn JJ, Johnson DL, Wapnir IL, Carlson RW, Stockdale FE, Hansen NM, Jeffrey SS. BMC Cancer. 2008: 8 66
• Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. Plevritis SK, Kurian AW, Sigal BM, Daniel BL, Ikeda DM, Stockdale FE, Garber AM. JAMA. 2006; 295 (20): 2374-84
• Phase I trial of uracil-ftorafur, leucovorin, and etoposide: an active all-oral regimen for metastatic breast cancer. Hartman AR, Grekowicz A, Lum BL, Carlson RW, Schurman C, Sikic BI, Shapiro R, Stockdale FE. Breast Cancer Res Treat. 2003; 82 (1): 61-9
• Regulation of myosin expression during myotome formation. Sacks LD, Cann GM, Nikovits W, Conlon S, Espinoza NR, Stockdale FE. Development. 2003; 130 (15): 3391-402
• Ventral axial organs regulate expression of myotomal Fgf-8 that influences rib development. Huang R, Stolte D, Kurz H, Ehehalt F, Cann GM, Stockdale FE, Patel K, Christ B. Dev Biol. 2003; 255 (1): 30-47